Company news
Frontier Biotechnologies Inc. news in 2026
Frontier Biotechnologies Inc.'s news releases, calls and decks from 2026, newest first.
(688221)"Frontier Biotechnologies Inc."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
November 19, 2026
(688221)"Frontier Biotechnologies Inc."Announcement on Notifying Creditors of Using Reserve Funds to Make Up for Losses
November 19, 2026
(688221)"Frontier Biotechnologies Inc."Report for Q3 2026
October 30, 2026
(688221)"Frontier Biotechnologies Inc."Notice on Convening the 1st Extraordinary General Meeting in 2026
October 30, 2026
(688221)"Frontier Biotechnologies Inc."Announcement on Use of Reserve Funds to Make Up for Losses
October 30, 2026
(688221)"Frontier Biotechnologies Inc."Announcement on Convening the Q3 2026 Performance Briefing
October 30, 2026
Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% and 5% Thresholds
September 29, 2026
Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Working Capital
September 3, 2026
Announcement on Use of Temporarily Idle Raised Funds for Cash Management
August 30, 2026
Voluntary Disclosure Announcement on Obtaining Drug Registration Certificate for FB3002 Loxoprofen Sodium Patches
August 20, 2026
Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% and 5% Threshold
August 12, 2026
Announcement on Returning Idle Raised Funds Used to Temporarily Supplement Current Capital
July 10, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 2, 2026
Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2025 Annual Report
June 12, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 22, 2026
Correction Announcement on Preliminary Earnings Estimate for 2025 and Earnings Preannouncement
April 24, 2026
Announcement on Changing the Disclosure Time of 2025 Annual Report and Report for Q1 2026
April 21, 2026
Announcement on Conducting Foreign Exchange Derivatives Trading Business
March 31, 2026
Announcement on Change of Scheduled Disclosure Time for Periodic Reports
March 30, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of FB7013 Injection
March 18, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on the Signing of an Authorization and License Agreement with GSK
February 23, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on Completing Industrial and Commercial Change Registration for Company Address Change and Issuance of New Business License
January 13, 2026
Announcement on Voluntary Disclosure of Acceptance Notice for the Clinical Trial Application for Domestic Production of Drugs of FB7013
December 31, 2025